Hilary Bricken
Source link

Hilary Bricken
Source link

These days, the options for dietary supplements are virtually limitless. And whatever substance you want to ingest, you can find it in gummy form. Omega-3? You bet. Vitamin C? Absolutely. Iron? Calcium? Zinc? Yes, yes, and yes. There are peach collagen rings and strawberry-watermelon fiber rings. There are brambleberry probiotic gummies and “tropical zing” gummy worms that promise to put you in “an upbeat mood.” There are libido gummies and menopause gummies. There are gummies that claim to boost your metabolism, to reinforce your immune system, to strengthen your hair, your skin, your nails. For kids, there are Transformers multivitamin gummies and My Little Pony multivitamin gummies.
I could go on. A simple search for gummy vitamins on the CVS website turns up more than 50 results. This is the golden age of gummies, and that can seem like a great thing. Who wouldn’t rather eat a peach ring than pop a pill? But if the notion that something healthy can taste exactly like candy seems too good to be true, that’s because it is.
Gummy supplements are a relatively new phenomenon, but gummy candies are not. Starch-based Turkish delight has been around since the late 18th century. In 1860s England, some of the earliest gummies were popularly known as “unclaimed babies” (because they were shaped like infants, many more of which apparently were unclaimed back then). In the 1920s, the German confectioner Hans Riegel founded Haribo and created the gelatin-based gummy bears still consumed around the world today. It would be another 60 years, though, before Haribo gummies arrived on American shores. In the decades that followed, gummy sweets became ubiquitous, taking almost every shape imaginable: worms, frogs, sharks, snakes, watermelons, doughnuts, hamburgers, french fries, bacon, Coke bottles, bracelets, Band-Aids, brains, teeth, eyeballs, genitalia, soldiers, mustaches, Legos, and, as in days of old, children.
Only in the late 1990s and early 2000s, though, did the supplement industry begin experimenting with gummies. The driving principle was not a new one: As Mary Poppins put it, “A spoonful of sugar makes the medicine go down.” Flintstones multivitamins have been around in their hard, chewable form since 1968; even if superior to pills, they basically taste like sweet, vaguely chemical chalk).
Gummy vitamins, on the contrary, are virtually indistinguishable from the treats they’re modeled on. You could pop men’s multis at the movies the same way you could Sour Patch Kids. (Or Starburst gummies, or Skittles gummies, or Jolly Rancher gummies—pretty much every non-chocolate candy now comes in gummy form.) Which is probably why they’ve become so popular, says Tod Cooperman, the president of ConsumerLab, a watchdog site that reviews supplements. When he founded ConsumerLab in 1999, gummy supplements hardly existed. Adult gummy vitamins didn’t hit the market until 2012. Now, Nina Puch, a scientist who formulates gummies for the food and pharmaceutical consulting company Knechtel, told me, three-quarters of the gummies she designs are supplements rather than candies. Gummy supplements are everywhere. They’re a rapidly expanding seven-plus billion dollar industry, and by 2027 that figure is projected to double.
But what makes gummy supplements appealing also makes them concerning. The reason they taste as good as candy, it turns out, is because on average, they can contain just as much sugar as candy does. The earliest gummy supplements, Cooperman told me, were basically just candy with vitamins sprayed on. They’ve come a long way since then: The active ingredients are now carefully integrated into the gummy itself by scientists such as Puch, and done so in a way that preserves as much of the gummy’s flavor and consistency as possible. But the nutritional essentials haven’t changed much—the average gummy vitamin contains about the same amount of sugar per serving as one piece of Sour Patch Kids does.
A little extra sugar is not the end of the world. But there’s also the danger of overdoses. Especially for children, it’s important that medicines and supplements not taste too good, Cora Breuner, a professor of pediatrics at the University of Washington, told me. Consumed in excess, many of the vitamins and nutrients delivered in supplements can be toxic. They have to strike an appropriate balance, neither tasting so bad that kids refuse to take them nor so good that they’ll want too much. Most gummy supplements seemingly fail the latter test, and not without consequences. Annual calls to Poison Control for pediatric melatonin overdoses have risen 530 percent over the past decade, in part, experts suggested to me last year, because of the hormone’s increased availability in gummy form. The overdose numbers are also up for multivitamins.
The risk of overdose can be greatly mitigated by simply taking care to store gummies where kids can’t get them. The more significant problem, Cooperman told me, is that gummies are simply a less reliable delivery mechanism than the alternatives. Vitamins and many other compounds degrade far faster in gummies’ half-liquid, half-solid state than in traditional pill or capsule form, he said, because gummies offer less protection from heat, light, moisture, and other contaminants.
To compensate, supplement makers will in many cases load their products with far more of a substance than advertised on the packaging. Some overage is to be expected with all supplements, but the margins for many gummy supplements are gargantuan. “Gummy vitamins were the most likely form to contain much more of an ingredient than listed,” ConsumerLab wrote in its 2023 review of multivitamins and multiminerals. Of the four gummy supplements reviewed, three contained nearly twice as much of the relevant substance as they were supposed to, and the fourth contained only around three-quarters as much.
A recent analysis of melatonin and CBD gummies yielded similar results: Some contained as much as 347 percent the amount of those substances stated on the label. Because the FDA generally does not regulate supplements as drugs, such wild variability is accepted in a way that it isn’t for actual pharmaceuticals. (In 2020, the FDA granted the first-ever Investigational New Drug Application for a gummy medication, though no such product appears to have come to market.) “If you have something that you need a specific amount of every time you take it, gummies are not the way to go,” says Pieter Cohen, a doctor at Cambridge Health Alliance, in Somerville, Massachusetts, and the lead author of the melatonin-CBD research. Taking too much of a supplement is generally not as dangerous as taking too much of a prescription drug, but, as Breuner noted, many supplements taken in sufficient excess can still be toxic. When I asked Cooperman what advice he had for people trying to navigate all of this, his answer was simple: “Don’t buy a gummy.”
Perhaps the rise of gummy supplements was inevitable. The supplement industry has become so big in part because it can promote its products as, say, boosting the immune system or supporting healthy bones, without subjecting them to the strict regulatory demands imposed on pharmaceuticals. Supplements blur the line between food and drug, and gummy supplements—designed and marketed on the premise that healthy stuff can and should taste as good as candy—only intensify that blurring. Cohen, for one, thinks the distinction is worth preserving. Calcium supplements should not go down as easy as Haribos. That may be a bitter pill to swallow, but not everything can taste like candy.
Jacob Stern
Source link

In the last election, President Biden promised to help the cannabis industry, two years into his term, he agreed to start the process. Now, joining the chorus of supporters, the American Nurses Association publicly supports rescheduling. The medical community has recognized medical marijuana has significant medical benefits, especially in the fight against opioids.
The American Nurses Association (ANA) joins bipartisan governors, Health and Human Service HHS), US Food & Drug Administration (FDA) in recommending the change.
ANA shared this in a public statement “Marijuana and its derivatives continue to be used to alleviate disease-related symptoms and side effects. The findings of anecdotal and controlled studies regarding the efficacy for patient use are mixed. Current federal regulations impede the research necessary to evaluate and determine the therapeutic use of marijuana and related cannabinoids. This position statement does not extend to the current debate on the legalization of marijuana for recreational purposes. The goal is to develop an evidence-based approach to its use in the treatment of disease and symptom management.”
RELATED: Science Says Medical Marijuana Improves Quality Of Life
Cannabis is currently a Schedule I drug, listed among those considered to have no accepted medical use and have a high potential for abuse. This makes marijuana classified on the same level as heroin, LSD, MDMA and psilocybin mushrooms.
Schedule III drugs are defined as having a moderate to low potential for physical and psychological dependence. They currently include ketamine, anabolic steroids, testosterone and acetaminophen with codeine.
Cannabis is currently a Schedule I drug, listed among those considered to have no accepted medical use and have a high potential for abuse. This makes marijuana classified on the same level as heroin, LSD, MDMA and psilocybin mushrooms.
Schedule III drugs are defined as having a moderate to low potential for physical and psychological dependence. They currently include Ibuprofen, ketamine, anabolic steroids, testosterone and acetaminophen with codeine.
RELATED: The Most Popular Marijuana Flavors
They continued to state “It is the shared responsibility of professional nursing organizations to speak for nurses collectively in shaping health care and to promulgate change for the improvement of health and health care”. Therefore, the ANA strongly supports:
The Drug Enforcement Agency (DEA) has made it clear they are the final authority for rescheduling and it seems the Biden administration has not pushed toward a quick resolution. It would be unprecedented for the DEA to go against the recommendations of HHS and the FDA, but it does mean it will follow or do it any time soon. The statement from the ANA adds to the pressure to act.
Amy Hansen
Source link

Quaker Oats is expanding a prior recall to include additional cereals, granola bars and snacks sold across the U.S. because they could be contaminated with salmonella.
The recalled products are sold throughout the 50 states, Puerto Rico, Guam and Saipan, Quaker Oats said in a notice posted Thursday by the U.S. Food and Drug Administration. See here for a full list of the recalled items, including those listed in an initial recall in mid-December.
Salmonella can cause serious illness if it enters the bloodstream, especially in young children, elderly people and those with weakened immune systems. The organism causes an estimated 1.3 million infections in Americans every year, resulting in an average of more than 26,000 hospitalizations and 420 deaths, CDC data shows.
Symptoms of infection usually occur within 12 hours to three days after eating contaminated food and include diarrhea, fever, nausea and abdominal cramps.
The recall includes Quaker Chewy Granola Bars, Cap’n Crunch Bars and select Cap’n Crunch cereals and oatmeal, Quaker Chewy Granola Breakfast cereals and Quaker Oatmeal Squares, Gamesa Marias Cereal, Gatorade Peanut Butter Chocolate Protein Bars, Munchies Munch Mix, and snack boxes that include these products, according to the Chicago-based company, a division of PepsiCo.
The recall does not include Quaker Oats, Quaker Instant Oats, Quaker Grits, Quaker Oat Bran, Quaker Oat Flour and Quaker Rice Snacks.
Consumers are urged to check their pantries for the recalled products and dispose of them. Additionally, consumers with any of the recalled products can contact Quaker Consumer Relations (9 a.m. – 4:30 p.m. CST, Mon.-Fri.) at 1-800-492-9322 or visit www.QuakerRecallUSA.com for additional information or product reimbursement.
Thanks for reading CBS NEWS.
Create your free account or log in
for more features.

States with legal marijuana want the tax revenue. Cannabis businesses need relief and help to continue and grow. The marijuana industry needs to move to the next level of legitimate industry. And consumers and patients need reliable, safe products which are the same from store to dispensary. This is the role of the federal government, but for the first two years, the Biden industry dithered. But the wheels have started turning and now they are more marijuana rescheduling hints.
RELATED: California or New York, Which Has The Biggest Marijuana Mess
The biggest hint is the breaking news came today during a short email sent from HHS. “Good afternoon and thank you for your patience,” a Department of Justice attorney said in an email on Thursday. “The agency has advised that it will release the letter and its enclosures in their entirety.”
The letter and its enclosures mean The Department of Health and Human Services (HHS) has agreed to release documents related to its recommendation to federally reschedule marijuana in its entirety. This seems to be do to potential litigation over a Freedom of Information Act (FOIA) request regarding the findings. The release adds pressure if the DEA plans to break precedent by not following HHS’s recommendation.
SAFER Banking advocate Senate Majority Leader Chuck Schumer shared HHS has recommended marijuana be moved from a Schedule I to a Schedule III controlled substance.
According to the DEA, Schedule I drugs have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse. The National Institute of Health disagrees on their website. And with rescheduling, the Food and Drug Administration (FDA) would become involved, while it is more of an onerous process, it would establish guidelines to make it more acceptable to major mainstream retailers and, more importantly, the medical community.
Additionally, rescheduling the drug would reduce or potentially eliminate criminal penalties for possession. Marijuana is currently classified as a Schedule I drug, alongside heroin and LSD.
RELATED: The Most Popular Marijuana Flavors
The industry agrees with Schumer who made a clear appeal when he shared the “DEA should now follow through on this important step to greatly reduce the harm caused by draconian marijuana laws.”
Terry Hacienda
Source link

Watch CBS News
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.

CBD has been touted as a gentle health aide a way to reduce stress, a way to sleep better and way to relax. Found everywhere from Amazon to Walmart, you can pick it up – especially when you feel the need for help. But do CBD gummies actually work?
CBD comes from cannabidiol, one of the two best-known active compounds derived from the marijuana plant. The other is tetrahydrocannabinol, or THC, which is the substance that that produces the “high” from marijuana. It can also be derived from hemp.
CBD does not get you high, but it can your consciousness. You may feel mellow, experience less pain, and be more comfortable. Some CBD products do contain small amounts of THC.
RELATED: Are CBD Drinks Legal?
Epidiolex is the only FDA-approved prescription CBD medicine, which among many things, means that it has a safety and efficacy profile that has been thoroughly evaluated in clinical trials. The rest of the CBD industry is going through growing pains there’s a mess going on with plenty of important guidelines, like dosage, purity and strength of the product. One of the many problems this disarray causes is the variability among CBD products. While some might provide noticeable effects, others might not even contain enough CBD to register in your system.
Yes, there is evidence CBD works for some conditions, but certainly not all the conditions it is being promoted for these days. According to different CBD gummy manufacturers, these products can provide relief for a wide range of ailments, including pain, anxiety, inflammation, insomnia and even depression. These statements have no scientific accuracy, however, since few tests have been conducted have been limited to CBD oil.
Anecdotally, plenty of people believe in the effect of CBD gummies, although the dosage still causes some issues. While some claim to feel positive effects after consuming two gummies, others might have to up the dosage until they feel something. With all the hype surrounding CBD gummies, this “something” might also be imagined; a placebo effect could be at work making you feel like you should be experiencing some sort of sensation because you just ingested cannabis.
RELATED: These Are The 4 Biggest Problems With CBD Products
Although few scientific tests have been conducted, CBD oil has been associated with plenty of positive side effects, and all of these gummies, if purchased correctly, contain a good amount of oil. You can also expect some clarity in the near future, since the industry is growing and learning the nuance exists between the different cannabis products and plants.
As usual, if you’re interested in trying out a new cannabis product, go slow. Purchase a bottle of reviewed CBD gummies and start off with a slow dose, checking in with your body for any changes and/or improvements. The worst thing which could happen is you ingest a ton of sugar and start to feel a little drowsy.
Maria Loreto
Source link

Watch CBS News
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.

The Supreme Court announced this morning that it would take up a pair of cases concerning access to mifepristone, the first pill in a two-pill regimen commonly used to induce abortion. Mifepristone has been the subject of a high-profile legal battle throughout the past year.
Crucially, the Court will not consider whether the U.S. Food and Drug Administration (FDA) erred in its initial 2000 approval of the Mifeprex (a brand name version of mifepristone) or its subsequent generic approval in 2019—which means the pill should remain legal no matter what SCOTUS decides. Rather, the Court will consider whether subsequent FDA rules regarding mifepristone’s prescription are valid.
At stake is whether doctors may prescribe mifepristone virtually, whether prescriptions can be shipped by mail, and whether it can be prescribed up to 10 weeks of pregnancy (instead of stopping at seven weeks).
Judge Matthew Kacsmaryk of the U.S. District Court for the Northern District of Texas held in April that the whole approval process was tainted. According to Kacsmaryk, the FDA erred when it approved the drug initially and when it approved generics in 2019. The judge also agreed with the Alliance for Hippocratic Medicine—the group that brought the case—that the FDA’s subsequent loosening of rules around prescribing mifepristone had been wrong.
Kacsmaryk suspended access to the pill entirely, but the Supreme Court paused enforcement of this decision while appeals were being resolved.
On appeal, the U.S. Court of Appeals for the 5th Circuit rejected Kacsmaryk’s ruling with regard to the initial FDA approval and its later generic approval. But the 5th Circuit upheld his ruling with regard to the later loosening of prescription rules, including the FDA’s decisions to allow lower-dose prescriptions, virtual prescriptions, and shipping the drug through the mail.
Following the 5th Circuit’s ruling, the Biden administration and Mifeprex maker Danco Laboratories asked the Supreme Court to take up the case and find that the 5th Circuit was wrong with regard to the parts of Kacsmaryk’s decision that it upheld. The Alliance for Hippocratic Medicine asked the Court to take up the case and find that the 5th Circuit was wrong with regard to the parts of Kacsmaryk’s decision that it rejected. The justices met last week to decide what to do.
Today, the Court announced that it would hear the issue, consolidating the cases from Danco laboratories and the Biden administration. It declined to hear the cross-petition filed by the Alliance for Hippocratic Medicine.
“What’s most important to know is that SCOTUS will not be looking at the original challenge to FDA approval of the drug,” notes Jessica Valenti of the Abortion Every Day substack. “Instead, they’ll review the 2016 and 2021 changes to restrictions around mifepristone, and whether or not the Alliance of Hippocratic Medicine (the anti-abortion group who brought the lawsuit) has standing.”
“The decision here will undoubtedly affect the availability of mifepristone, but the case no longer includes the question of whether the FDA should have approved mifepristone for the purpose of terminating pregnancies in the first place,” explains Jonathan H. Adler at The Volokh Conspiracy.
This is—as Law Dork’s Chris Geidner points out—”a best-case scenario for abortion rights supporters.” It leaves intact the general approval of mifepristone while opening up the possibility of reversing the 5th Circuit’s ruling regarding eased access to the drug.
Elizabeth Nolan Brown
Source link

The same bacteria that led to the 2022 baby formula recall and sparked shortages across the U.S., this year has caused the death of one newborn in Kentucky and brain damage in a Missouri infant, according to federal health officials.
Food and Drug Administration (FDA) officials confirmed Thursday that two cases of life-threatening infections caused by Cronobacter sakazakii have been reported in 2023, both babies who consumed powdered formula made by Abbott Nutrition, the company involved in the 2022 recall. For the reported cases this year, both Abbott and the FDA have found no link to the formula maker’s facilities, saying contamination likely happened after the containers were opened at home.
In February 2022, Abbott initiated a voluntary recall of its powder baby formulas for brands including Similac, Alimentum and EleCare that were manufactured at one of the company’s facilities in Sturgis, Michigan. The recall was due to the presence of Cronobacter sakazakii, which is a rare bacteria that the U.S. Centers for Disease and Control and Prevention (CDC) said has been found in powdered infant formula, skimmed milk powder, herbal teas and starches, and is “lethal for infants and can be serious among people with immunocompromising conditions and the elderly.”
The FDA said on Thursday that there was no reason to issue new recalls for baby formula after an investigation found, despite two infants becoming infected by the bacteria this year, there was no evidence that the infections were linked to manufacturing, the Associated Press reported.
“There is no indication of a broader public health concern related to this product at this time,” the FDA said in a statement.
Newsweek reached out via email on Saturday to the FDA and CDC for comment.
In March, then 6-week-old Mira White, of Sikeston, Missouri, was diagnosed with a serious brain infection caused by the bacteria, which was found in an open container of Similac NeoSure formula in the baby’s home, according to the AP.
Mira’s mom told the AP that since her daughter became infected, she has suffered numerous seizures and said that brain scans show neurological damage caused by the infection.
In Kentucky, health officials notified the CDC in November that a baby who consumed Similac Total Comfort powdered formula had died after being infected with Cronobacter sakazakii, according to the AP.
John Koval, a spokesperson for Abbott, told Newsweek in an email on Saturday night that the reported infections in Missouri and Kentucky have not been linked to the company’s manufacturing facilities.
“As Abbott and FDA have said, the unopened product was tested and came back negative, and the infections have not been linked to the manufacturing environment,” Koval said. “Cronobacter is naturally and commonly found in the environment, and can find its way into infant formula after the packaging is opened. We encourage parents and caregivers to consult resources published by the FDA and CDC on how to safely handle, store and prepare infant formula.”
What is Cronobacter sakazakii?
Cronobacter sakazakii is a germ found naturally in the environment and can live in dry foods, including powdered infant formula and powdered milk, according to the CDC.
The CDC notes that powdered formula is not sterile, meaning it could become accidentally contaminated during the manufacturing process or after the container is opened at home.
Cronobacter sakazakii can live on surfaces, such as kitchen counters or sinks, and in water, according to the CDC.
Frequently and thoroughly cleaning surfaces, hands and baby products help reduce the risk. The CDC also advises parents to avoid setting formula scoops on the counter or in the sink, to keep lids and scoops clean and completely dry, and close containers of formula as soon as possible after using them.
What is the risk?
While the CDC states that Cronobacter infections are rare, they can be life-threatening in newborns. Serious infections in babies usually occur in the first few weeks of life.
Yearly, between two to four cases are reported to the CDC, which adds that this figure may not reflect the true number of illnesses because most hospitals and laboratories are not required to report Cronobacter infections to health departments.
Infants who are born prematurely and babies with weakened immune systems are more likely to develop serious symptoms if infected.
Signs of Cronobacterillness in babies usually start with a fever and poor feeding, excessive crying, or very low energy, according to the CDC, which warns that some infants may also have seizures. An infant with these symptoms should be seen by a medical provider as soon as possible.
Cronobacter germs can lead to sepsis, a dangerous blood infection, and cause the lining surrounding the brain and spinal cord to swell, also known as meningitis. Babies younger than two months are most at risk for developing meningitis if they get sick from Cronobacter.
Newsweek is committed to challenging conventional wisdom and finding connections in the search for common ground.
Newsweek is committed to challenging conventional wisdom and finding connections in the search for common ground.

The painful, inherited blood disorder afflicts mostly Black people in the U.S.

Consumers who eat cantaloupe are advised to be on high alert following a spate of government warnings over a deadly salmonella outbreak linked to the fruit.
U.S. health officials have ordered sweeping recalls of potentially contaminated whole and pre-sliced cantaloupes over the past few weeks, in addition to urging consumers on Thursday to toss out any products containing the melon, recall notices from officials show. The flurry of warnings has prompted major grocery sellers such as Kroger, Trader Joe’s and Walmart to continue removing products containing the melon from store shelves.
Bacteria-harboring cantaloupes have been linked to at least 117 illnesses, including 61 hospitalizations and two deaths across 34 U.S. states, and those numbers could grow, the Centers for Disease Control and Prevention said Thursday in a statement.
Here’s what to know about the latest rash of cantaloupe recalls, and how to know if you should save or toss that fruit in your fridge.
Following an outbreak of severe bacterial infections linked to the fruits, the CDC is warning consumers to steer clear of pre-cut cantaloupe if they are unsure of whether it is from a distributor whose product has been recalled.
The guidance follows previous orders by U.S. health officials to recall whole cantaloupes from several brands, including Malichita and Rudy, which prompted several nationwide grocery chains to recall their own products containing pre-cut cantaloupes. Most recently, Sprouts Farmers Market and Trader Joe’s on Wednesday pulled select fresh-cut products made from whole cantaloupes off their shelves, according to an FDA notice.
Cut Fruit Express of Inver Grove Heights, Minnesota, on Wednesday recalled products containing cantaloupe, including Caribou Coffee Fruit Mix CHPG 6.5oz; Cut Fruit Express Brand 6.5oz, 15oz, 16oz, 32oz packages of fruit mix; and food service packages of 5lb-tray, 10lb-bag, 25lb-Pail, all of which could be contaminated with salmonella.
Whole fresh cantaloupes with Malichita, Rudy, “4050” and “Product of Mexico/produit du Mexique” labels are not safe to consume and should be thrown away, the FDA said.
In addition, products containing pre-cut cantaloupe such as fruit salads may pose a salmonella risk to consumers, according to the agency. Since November, there have been at least three waves of recalls issued over pre-cut cantaloupe by major grocery stores, including Kroger, Trader Joe’s, Sprouts Farmer Market, Aldi, and Walmart, according to the FDA.
The FDA is advising consumers to toss out any cantaloupe that cannot be identified by brand.
“If you cannot tell if your cantaloupe, including pre-cut cantaloupe or products containing pre-cut cantaloupe is part of the recall, do not eat or use it and throw it away,” the agency said Thursday in a statement.
In addition to throwing out the melon, that FDA advises people to wash any surfaces that may have come into contact with the cantaloupe, using hot, soapy water or a dishwasher, the agency said.
Salmonella, or salmonellosis, is a bacterial infection that affects the intestinal tract, according to the Mayo Clinic, a nonprofit medical research center. Symptoms include diarrhea, fever and stomach cramps, which usually begin between eight and 72 hours after exposure to the bacteria.
Not everyone who contracts salmonella experiences symptoms, according to the Mayo Clinic. Children under age five, the elderly and those with weakened immune systems are more at risk of developing severe illnesses that require medical care or hospitalization.
People who get salmonella should rest and drink plenty of fluids to avoid dehydration, according to the Cleveland Clinic. The infection usually resolves on its own in a few days.

WASHINGTON, November 29, 2023 (Newswire.com)
–
Today, the Food and Drug Administration (FDA) promoted Dr. Namandjé Bumpus, Ph.D., to Principal Deputy Commissioner. Farah K. Ahmed, President and CEO of Fragrance Creators Association (Fragrance Creators), shared the following: “On behalf of Fragrance Creators’ staff and member companies, I want to extend my warmest congratulations to Dr. Bumpus for this well-deserved promotion. As the FDA noted in its announcement, Dr. Bumpus is a champion of science, an advocate for public health, and an impressive scientist; we wholeheartedly agree.”
The announcement came as the FDA works to develop, advance, and implement key public health initiatives, including the Modernization of Cosmetics Regulation Act (MoCRA). “Fragrance Creators values collaborating with Dr. Bumpus as we continue to serve as a resource to the Agency. She has been a thoughtful leader and a scientist of the highest caliber,” said Ahmed. “Personally, as a former FDA employee, I am delighted to see the agency also prioritize diversity — an inspiration for all women, especially women of color — in this role.”
Fragrance plays an important role in home care, cosmetics, and personal care products, products that impact everyday life, nurture skin health and hygiene, empower self-expression and confidence, and deliver generational delight to billions of people every day. Fragrance Creators recognizes the FDA’s and Dr. Bumpus’ commitment to advancing public health predicated on best-in-class science, as our members remain dedicated to ensuring we continue to support the agency — for people, perfume, and the planet.
Fragrance Creators looks forward to continuing our engagement with Dr. Bumpus as she transitions from Chief Scientist into her new role as Principal Deputy Commissioner, succeeding Dr. Janet Woodcock, M.D., when Dr. Woodcock retires early next year. “We also want to thank Dr. Woodcock for the tremendous advancements she has made for public health, science, and women in science,” said Ahmed. “We wish her well in this next chapter.”
###
Fragrance Creators Association is the trade association representing the majority of fragrance manufacturing in North America. We also represent fragrance-related interests along the value chain. Fragrance Creators’ member companies are diverse, including large, medium, and small-sized companies that create, manufacture, and use fragrances and scents for home care, personal care, home design, fine fragrance, and industrial and institutional products, as well as those that supply fragrance ingredients, including natural extracts and other raw materials that are used in perfumery and fragrance mixtures. Fragrance Creators established and administers the Congressional Fragrance Caucus, ensuring ongoing dialogue with members of Congress and staff. Fragrance Creators also produces The Fragrance Conservatory, the comprehensive digital resource for high-quality information about fragrance — www.fragranceconservatory.com. Learn more about Fragrance Creators at fragrancecreators.org — for people, perfume, and the planet.
Source: Fragrance Creators Association

The FDA has expanded its list of eye drops recalled in 2023 because the products could be tainted with bacteria.
Store-brand products sold at retailers including CVS, Rite Aid, Target and Walmart are included in the latest recall, posted on Wednesday by the federal safety agency. The recall by Kilitch Healthcare India cited “safety concerns” after FDA investigators found unsanitary conditions at the facility where the products were made.
The FDA has cited a “risk of eye infections that could result in partial vision loss or blindness” in cautioning consumers against using the now-recalled products in late October. FDA investigators found bacteria in samples taken from the production plant, the agency noted in its warning. As of Nov. 13, Kilitch said it hasn’t received any reports of adverse health effects linked to the recall.
Many of the eye drops are likely no longer in stores, as the FDA said CVS, Rite Aid and Target were removing the products from store shelves and websites.
The recall notice urged distributors and retailers to stop selling the products and for consumers to return them.
Amazon said its website was no longer offering seven eye drop products after the FDA warned the e-commerce giant that their distribution violated federal regulations and raised public health concerns.
The pulled products named in the agency’s letter are: Similasan Pink Eye Relief, The Goodbye Company Pink Eye, Can-C Eye Drops, Optique 1 Eye Drops, OcluMed Eye Drops, TRP Natural Eyes Floaters Relief and Manzanilla Sophia Chamomile Herbal Eye Drops.
“We require all products offered in our store to comply with applicable laws and regulations. The products in question have been investigated and removed,” an Amazon spokesperson told CBS MoneyWatch on Friday in an emailed statement.
The FDA’s warning prompted Cardinal Health in early November to recall six Leader brand eye products, while Harvard Drug Group recalled Rugby Laboratories brand eye drops.
Those warnings included the agency in August advising people not to buy “Dr. Berne’s MSM Drops 5% Solution” and “LightEyez MSM Eye Drops – Eye Repair,” saying they presented serious health risks, including vision- and life-threatening infections.
The recalls are among eight such actions involving the FDA and eye drops this year, starting with news in early February that the Centers for Disease Control and Prevention (CDC) was investigating a cluster of infections related to artificial tears.
Federal inspectors found dozens of problems at Indian manufacturer Global Pharma Healthcare amid the multistate outbreak of rare and extensively drug-resistant bacteria linked by eye drops made by the company, which were branded as EzriCare and Delsam Pharma.
The CDC ultimately identified 81 patients in 18 states. Of that that number, four people died, 14 reported vision loss and another four had to have their eyeballs surgically removed, the agency said in its last update in May.
Eye drops must be sterile to be safe, and therefore need “much finer oversight on the manufacturing side” to ensure the products aren’t contaminated, Carri Chan, a business professor at Columbia University, recently told CBS MoneyWatch.
The FDA maintains an updated list of eye drop products that people should get rid of. Users can also consult an eye drop manufacturer’s website to check if a product has been recalled.
Dr. Christopher Starr, a spokesperson for the American Academy of Ophthalmology, said people should seek medical help immediately if they have adverse reactions to eye drops, such as discharge, redness or pain, which can indicate an infection. People should also check a product’s expiration date before use.
Consumers with questions about the recall can contact Kilitch at regulatory@kilitchhealthcare.com or Velocity Pharma, Kilitch’s distributor, at regulatory@velocitypharma.com. Eye drop users who experience adverse reactions can file a report with the FDA online or by downloading and mailing a pre-addressed form.
—Elizabeth Napolitano contributed to this report.

Another eye drop recall is pulling 27 products from store shelves, including store-brand products sold at retailers such as CVS, Rite Aid, Target and Walmart, with the recall coming about three weeks after the U.S. Food and Drug Administration warned people not to buy or use the eye drops.
Kilitch Healthcare India is recalling eye drops with expiration dates ranging from November 2023 to September 2025, citing “safety concerns” due to FDA investigators finding unsanitary conditions at the facility where the products were made, according to a news release posted Wednesday by the agency. You can see the full list of recalled eye drops here.
The FDA cited a “risk of eye infections that could result in partial vision loss or blindness” in urging against use of the products in late October, with the agency saying its investigators found unsanitary conditions and “positive bacterial test results” from areas of an unidentified manufacturing facility. As of Nov. 13, Kilitch said it hasn’t received any reports of adverse health effects linked to the recall.
Some of the eye drops may have already been removed from stores, as earlier this month the FDA said CVS, Rite Aid and Target were taking the products off their shelves and websites.
The recall notice said that distributors and retailers that have any of the recalled products should stop distributing them. Consumers, meanwhile, should stop using the recalled eye drops and return the products to where they purchased them, the FDA said.
Bloomberg News reported that Kilitch produced the eye drops in an unsanitary factory in India where some workers went barefoot and others made up test results that purported to show the products were sterile.
The FDA’s warning prompted Cardinal Health in early November to recall six Leader brand eye products, while Harvard Drug Group recalled Rugby Laboratories brand eye drops.
The FDA earlier this year announced a spate of recalls of eye drop products linked to four deaths and multiple cases of vision loss. In August, it warned against using two additional eye drop products because of the risk of bacterial or fungal contamination.
Eye drop products, which must be sterile in order to be safe, require “much finer oversight on the manufacturing side in order to ensure that there’s no contamination whatsoever,” Carri Chan, a business professor at Columbia University, told CBS MoneyWatch last week in reference to the spate of recalls.
The FDA keeps an updated list of eye drop products that consumers should discard. Users can also consult an eye drop manufacturer’s website to check if a product has been recalled.
Dr. Christopher Starr, a spokesman for the American Academy of Ophthalmology, said people should seek medical help immediately if they experience adverse reactions to their eye drops, told CBS MoneyWatch. Signs of an infection typically include discharge, redness or pain. Consumers should also check a product’s expiration date before use.
Consumers with questions about the recall can contact Kilitch at regulatory@kilitchhealthcare.com or Velocity Pharma, Kilitch’s distributor, at regulatory@velocitypharma.com. Eye drop users who experience adverse reactions can file a report with the FDA online or by downloading and mailing a pre-addressed form.
—Elizabeth Napolitano contributed to this report.

Studies show that many doctors either tend to overestimate the amount of weight that can be lost with obesity drugs or are simply clueless.
Current options for weight-loss medications include the ridiculously named Qsymia, a combination of phentermine (the phen in fen-phen) and topiramate, a drug that can cause seizures if you stop it abruptly. Qsymia was “explicitly rejected” multiple times for safety reasons in Europe “because of concerns about the medicine’s long-term effects on the heart and blood vessels” but, at the time of making my video Are Weight Loss Pills Effective?, remains available for sale in the United States. Belviq is in a similar boat—allowed in the United States but not in Europe due to “concerns about possible cancers, psychiatric disorders, and heart valve problems…”
Belviq is sold in the United States for about $200 a month. If you think that’s a lot, there’s Saxenda, which requires daily injections and is listed at the low, low price of only $1,281.96 for a 30-day supply. It carries a black box warning, the FDA’s strictest caution about potentially life-threatening hazards, for thyroid cancer risk. Paid consultants and employees of the company that makes it argue the greater number of breast tumors found among drug recipients may be due to “enhanced ascertainment,” meaning easier breast cancer detection just due to the drug’s effectiveness.
Contrave is another option if you ignore its black box warning about a potential increase in suicidal thoughts. Then there’s Alli, the drug that causes fat malabsorption, thereby resulting in side effects “including fecal urgency, oily stool, flatus with discharge, and fecal incontinence”—Alli can be your ally in anal leakage. The drug evidently “forces the patient to use diapers and to know the location of all the bathrooms in the neighborhood in an attempt to limit the consequences of urgent leakage of oily fecal matter.” A Freedom of Information Act exposé found that although company-sponsored studies claimed that “all adverse events were recorded,” one trial apparently conveniently failed to mention 1,318 of them.
What’s a little bowel leakage, though, compared to the ravages of obesity? As with anything in life, it’s all about risks versus benefits. However, in an analysis of more than a hundred clinical trials of anti-obesity medications that lasted up to 47 weeks, drug-induced weight loss never exceeded more than nine pounds. That’s a lot of money and a lot of risk for just a few pounds. Since you aren’t treating the underlying cause—a fattening diet—when people stop taking these drugs, the weight tends to come right back, so you’d have to take them every day for the rest of your life. But people do stop taking them. Using pharmacy data from a million people, most Alli users stopped after the very first purchase and most Meridia users didn’t even make it three months. Taking weight-loss meds is so disagreeable that 98 percent of users stopped taking them within the first year.
Studies show that many doctors tend to overestimate the amount of weight that can be lost with these drugs or are simply clueless. One reason may be that some clinical practice guidelines go out of their way to advocate prescribing medications for obesity. Are they seriously recommending drugging a third of Americans—more than 100 million people? You may not be surprised to learn that the principal author of the guidelines has a “significant financial interest or leadership position” in six separate pharmaceutical companies that all (coincidently) work on obesity drugs. In contrast, independent expert panels, like the Canadian Task Force on Preventive Health Care, explicitly recommend against weight-loss drugs, given their poor track record of safety and efficacy.
In case you missed my related video, check out Are Weight Loss Pills Safe?.
As with all lifestyle diseases, it’s better to treat the underlying cause, which, in the case of obesity, is a fattening diet. For an example of what’s possible with a healthy diet intervention, see Flashback Friday: The Weight Loss Program That Got Better with Time.
Check out the related videos below for more about weight loss.
Michael Greger M.D. FACLM
Source link

Twenty-two children in 14 states have reportedly fallen ill after eating applesauce pouches “tainted” with lead. According to AP News, the CDC issued a health alert for parents and doctors on Monday, November 13.
According to the CDC, multiple states have reported cases to the US Food and Drug Administration (FDA) linking “high blood lead levels” to children who have eaten “recalled cinnamon-containing applesauce products.”
The FDA reports that the affected applesauce products include “Recalled WanaBana apple cinnamon fruit puree pouches, Recalled Schnucks-brand cinnamon-flavored applesauce pouches and variety pack and Recalled Weis-brand cinnamon applesauce pouches.”
🚨Additional Recall Alert for Applesauce Puree Pouches Due to Lead Contamination
Recall now includes WanaBana apple cinnamon fruit puree pouches, Schnucks brand cinnamon-flavored applesauce pouches & variety pack, & Weis brand cinnamon applesauce pouches.https://t.co/8NksSwKSAu pic.twitter.com/CesMd9MJGo
— Tompkins County Whole Health (@TCWholeHealth) November 8, 2023
According to AP News, 22 children have been sickened by the lead-tainted applesauce pouches thus far. The outlet reports that the children are between the ages of between the ages of 1-3.
The FDA reports that children who have been impacted by lead poisoning may not have “obvious immediate symptoms.” However, short-term exposure to lead can lead to symptoms such as headaches, vomiting, abdominal pain/colic, and anemia in children.
Long-term exposure can lead to muscle aches, burning or weakness, constipation, tremors, and even weight loss, among other symptoms.
The CDC adds that the effects of lead poisoning in children “may continue into adulthood.”
According to the CDC, the 22 reported cases come from 14 states.
“Alabama, Arkansas, Louisiana, Maryland, Missouri, New Mexico, New York, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, Texas, and Washington,” the CDC‘s official website reads as the total 14.
Furthermore, AP News notes that the impacted applesauce products have been sold in-store and online. The FDA states that consumers should not “eat, sell, or serve” the WanaBana, Schnucks, or Weis applesauce pouches but instead immediately “discard them.”
The FDA also recommends that consumers thoroughly search their homes for these products as they may have been stored away due to their longer shelf life.
Furthermore, the FDA recommends that parents who are suspicious their children may have eaten the impacted products bring them to a medical professional for blood testing. The association also urges parents to immediately call a doctor if their children show signs of “lead toxicity.”
The association adds, “updates to this advisory will be provided as they become available.”
Jadriena Solomon
Source link

Why don’t more people take the weight-loss medications currently on the market?
Despite the myriad menus of FDA-approved medications for weight loss, they’ve only been prescribed for about 1 in 50 patients with obesity. We tend to worship medical magic bullets in the United States, so what gives? As I discuss in my video Friday Favorites: Are Weight-Loss Supplements Safe and Effective?, one of the reasons anti-obesity drugs are so “highly stigmatized” is that, historically, they’ve been anything but magical and the bullets have been blanks—or worse.
To date, most weight-loss drugs that were initially approved as safe have since been pulled from the market for unforeseen side effects that turned them into a “threat to public health.” As you may remember from my video Brown Fat: Losing Weight Through Thermogenesis, it all started with DNP, a pesticide with a promise to safely melt away fat that melted away people’s eyesight instead. (That actually helped lead to the passage of the landmark Food, Drug, and Cosmetic Act in 1938.) Thanks to the internet, DNP has made a comeback with “predictably lethal results.”
Then came the amphetamines. Currently, more than half a million Americans may be addicted to amphetamines like crystal meth, but the “original amphetamine epidemic was generated by the pharmaceutical industry and medical profession.” By the 1960s, drug companies were churning out about 80,000 kilos of amphetamines a year, which is nearly enough for a weekly dose for every man, woman, and child in the United States. Billions of doses a year were prescribed for weight loss, and weight-loss clinics were raking in huge profits. A dispensing diet doctor could buy 100,000 amphetamine tablets for less than $100, then turn around and sell them to patients for $12,000.
At a 1970 Senate Hearing, Senator Thomas Dodd (father of “Dodd-Frank” Senator Chris Dodd) suggested that America’s speed freak problem “was no by means an ‘accidental development’: ‘Multihundred million dollar advertising budgets, frequently the most costly ingredient in the price of a pill, have, pill by pill, led, coaxed and seduced post-World War II generations into the ‘freaked-out’ drug culture…’” I’ll leave drawing the Big Pharma parallels to the current opioid crisis as an exercise for the viewer.
Aminorex was a widely-prescribed appetite suppressant before it was pulled for causing lung damage. Eighteen million Americans were on fen-phen before it was pulled from the market for causing severe damage to heart valves. Meridia was pulled for heart attacks and strokes, Acomplia was pulled for psychiatric side effects, including suicide, and the list goes on, as you can see below and at 2:51 in my video.
The fen-phen debacle resulted in “some of the largest litigation pay-outs ever seen in the pharmaceutical industry, with individual amounts of up to US$200,000 and a total value of ~US$14 billion,” but that’s all baked into the formula. If you read the journal PharmacoEconomics (and who doesn’t!), you may be aware that a new weight-loss drug may injure and kill so many that “expected litigation cost” could exceed $80 million, but Big Pharma consultants estimate that if it’s successful, the drug could bring in more than $100 million, so do the math.
What does work for weight loss? I dive deep into that and more in How Not to Diet. For more of my videos on weight loss, check out the related videos below.
Michael Greger M.D. FACLM
Source link

Watch CBS News
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.

Remember the “epidemic” of underage nicotine vaping? For years, activists, politicians, and public health officials have been warning that a surge in e-cigarette use by teenagers would hook a generation of young people on nicotine and encourage them to smoke.
That never happened, as new federal survey data confirm. But policies adopted in response to that overblown threat continue to undermine the harm-reducing potential of vaping products by making them less attractive to current and former smokers.
According to the latest National Youth Tobacco Survey, which is overseen by the Centers for Disease Control and Prevention (CDC), 10 percent of high school students reported past-month e-cigarette use in 2023, down from 14 percent last year and more than 27 percent in 2019. Among middle school students, the 2023 rate was 4.6 percent, less than half the 2019 rate.
How many of those past-month vapers might reasonably be described as addicted to nicotine? A quarter of them—less than 2 percent of all respondents—reported vaping every day in the previous month, meaning that, as usual, the vast majority were occasional users.
This does not look like an epidemic of nicotine addiction. Nor did the fear that vaping would lead to smoking pan out.
Even at the peak of underage vaping, the downward trend in adolescent smoking not only continued but accelerated. In the 2023 survey, less than 2 percent of high school students reported smoking cigarettes in the previous month—down from 16 percent in 2011 and (according to a survey of 10th- and 12th-graders) more than 30 percent in 1997.
The CDC describes vaping as “tobacco product use,” even though e-cigarettes do not contain tobacco, and lumps it in with smoking, even though it does not involve combustion. But while the CDC is loath to admit it, the shift from smoking to vaping—in any age group—is indisputably an improvement in terms of health risks.
The Food and Drug Administration (FDA) acknowledges that vaping is far less hazardous than smoking, and it supposedly is committed to maintaining the availability of what it calls “electronic nicotine delivery systems” (ENDS) as a potentially lifesaving alternative for cigarette smokers. Yet to deter underage use, the FDA so far has approved only tobacco-flavored ENDS, even though former smokers overwhelmingly prefer other flavors.
That policy makes ENDS less appealing to people who already have switched from smoking to vaping or might be interested in doing so. The results are predictable: A recent FDA-supported study of sales data from across the country found that state and local restrictions on ENDS flavors were associated with increased purchases of conventional cigarettes.
“We find that ENDS flavor policies reduce flavored ENDS sales as intended, but also increase cigarette sales across age groups,” the researchers reported. “As cigarettes are much more lethal than ENDS, the high rate of substitution estimated here suggests that, on net, any population health benefits of ENDS flavor policies are likely small or even negative.”
Although “flavored ENDS products remain widely available in states that do not prohibit their sales,” the study’s authors noted, the FDA seems to be “paving a path towards a de facto national ENDS flavor prohibition.” That policy, they said, entails an “inequitable tradeoff” because it “prioritizes youth over the 11.2% of US adults [who] smoke.”
Since the FDA has not made a serious effort to enforce its de facto ban against the thousands of suppliers who are theoretically violating it, adults can still purchase ENDS in a wide variety of flavors from vape shops, tobacconists, and online vendors. Preserving those options for adults is consistent with efforts to reduce underage consumption, as the ongoing decline in adolescent vaping shows.
The flavor restrictions embraced by regulators and legislators threaten to harm public health in the name of protecting it. To save teenagers from an exaggerated danger, bureaucrats and politicians are sacrificing the interests, and perhaps the lives, of adult smokers across the country.
© Copyright 2023 by Creators Syndicate Inc.
Jacob Sullum
Source link